The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Tumor-informed ctDNA monitoring in lung cancer surveillance
Luis Raez, MD, Memorial Cancer Institute, Pembroke Pines, FL, discusses the use of personalized, tumor-informed circulating DNA (ctDNA) analysis for monitoring treatment outcomes in lung cancer. In a retrospective cohort, ctDNA demonstrated high concordance with systemic imaging in patients with non-small cell lung cancer, particularly among those receiving targeted therapies, while correlation with brain imaging was lower. These findings suggest ctDNA may complement conventional imaging, providing earlier insights into progression or recurrence. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, that’s another important area. We just discussed when you are diagnosed how we can classify your cancer with genetic studies. But now what we can do also is we can track your tumor. We do minimal residual disease. We can find after your surgery, if you have a still tumor in your body, even if we don’t see it in the CT scan, but we can find it in the blood...
Yeah, that’s another important area. We just discussed when you are diagnosed how we can classify your cancer with genetic studies. But now what we can do also is we can track your tumor. We do minimal residual disease. We can find after your surgery, if you have a still tumor in your body, even if we don’t see it in the CT scan, but we can find it in the blood. That we call minimal residual disease. So basically, we have a poster. We have like around 80 cancer patients that we are following minimal residual disease and compare with imaging during treatment. In other words, the tumors are growing because the treatment is failing. We can see in the blood how the amount of ctDNA, or circulating tumoral DNA, goes up. We see patients are responding to treatment. We can see how the ctDNA goes down. So that’s amazing because that means that we may not need in the near future to do CT scans every three months, as we do now at standard care, to assess tumors. So we can save the patient exposure to radiation and all the money that we use for CT scans can be invested in this type of technology, this type of liquid biopsy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
